Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Historical Review of Pharmacological Development and Dosimetry of Psma-Based Theranostics for Prostate Cancer Publisher



Vahidfar N1 ; Fallahpoor M1 ; Farzanehfar S1 ; Divband G2 ; Ahmadzadehfar H3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Nuclear Medicine, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Qaem Educational, Research and Treatment Center, Mashhad, Iran
  3. 3. Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany

Source: Journal of Radioanalytical and Nuclear Chemistry Published:2019


Abstract

Many efforts have been made to introduce an appropriate radiopharmaceutical as a theranostic agent for metastatic castration-resistant prostate cancer. Prostate-specific membrane antigen (PSMA) is expressed in most types of prostate cancer (PCa), with only 5–10% of primary PCa lesions being PSMA-negative. When radiolabeled, PSMA tracers show outstanding features in terms of their theranostic properties. In this study, we discuss the pharmacological and physical characteristics of various radiopharmaceuticals used for the theranostic treatment of PCa. This review aims to outline the developments from the first radiopharmaceuticals PCa, including monoclonal antibodies, to the final gold standard in PSMA-based theranostics. © 2019, Akademiai Kiado, Budapest, Hungary.
Related Docs
View other Related Docs
1. Design, Synthesis, Radiolabeling and Biological Evaluation of New Urea-Based Peptides Targeting Prostate Specific Membrane Antigen, Bioorganic Chemistry (2020)
2. Factors Predicting Biochemical Response and Survival Benefits Following Radioligand Therapy With [177Lu]Lu-Psma in Metastatic Castrate-Resistant Prostate Cancer: A Review, European Journal of Nuclear Medicine and Molecular Imaging (2021)
3. An Impressive Approach in Nuclear Medicine: Theranostics, PET Clinics (2021)
4. Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends, Cancers (2021)
5. The Iranian Society of Nuclear Medicine Practical Guideline on Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Using 177Lu-Psma, Iranian Journal of Nuclear Medicine (2018)
6. Bone Metastasis in Prostate Cancer: Bone Scan Versus Pet Imaging, Seminars in Nuclear Medicine (2024)
7. Automated Segmentation of Lesions and Organs at Risk on [68Ga]Ga-Psma-11 Pet/Ct Images Using Self-Supervised Learning With Swin Unetr, Cancer Imaging (2024)
8. Theranostic Advances in Breast Cancer in Nuclear Medicine, International Journal of Molecular Sciences (2021)
Experts (# of related papers)
View all Related Experts
Saeed Farzanefar (6)
Parham Geramifar (6)
Other Related Docs
9. Targeted Radioligand Therapy: Physics and Biology, Internal Dosimetry and Other Practical Aspects During 177Lu/225Ac Treatment in Neuroendocrine Tumors and Metastatic Prostate Cancer, Theranostics (2025)
10. Multiphasic 68Ga-Psma Pet/Ct in the Detection of Early Recurrence in Prostate Cancer Patients With a Psa Level of Less Than 1 Ng/Ml: A Prospective Study of 135 Patients, Journal of Nuclear Medicine (2020)
11. Various Aspects of Fasting on the Biodistribution of Radiopharmaceuticals, Current Drug Metabolism (2022)
12. Passive-Specific Immunotherapy With Monoclonal Antibodies for Prostate Cancer: A Systematic Review, Journal of Oncology Pharmacy Practice (2019)
13. Radiomics and Artificial Intelligence in Radiotheranostics: A Review of Applications for Radioligands Targeting Somatostatin Receptors and Prostate-Specific Membrane Antigens, Diagnostics (2024)
14. Novel and Efficient Method for Solid Phase Synthesis of Urea-Containing Peptides Targeting Prostate Specific Membrane Antigen (Psma) in Comparison With Current Methods, Iranian Journal of Pharmaceutical Research (2018)
15. Necessity of Pelvic Lymph Node Irradiation in Patients With Recurrent Prostate Cancer After Radical Prostatectomy in the Psma Pet/Ct Era: A Narrative Review, Biomedicines (2023)
16. Diagnostic Performance of [18F]Fluorocholine and [68Ga]Ga-Psma Pet/Ct in Prostate Cancer: A Comparative Study, Journal of Clinical Medicine (2020)
17. Synthesis and Radiolabeling of Glu-Urea-Lys With 99Mtc-Tricarbonyl-Imidazole-Bathophenanthroline Disulfonate Chelation System and Biological Evaluation As Prostate-Specific Membrane Antigen Inhibitor, Cancer Biotherapy and Radiopharmaceuticals (2023)
18. Computationally Efficient Collimator-Detector Response Compensation in High Energy Spect Using 1D Convolutions and Rotations, Physics in Medicine and Biology (2025)
19. 99Mtc-Psma Spect/Ct Versus 68Ga-Psma Pet/Ct in the Evaluation of Metastatic Prostate Cancer, Clinical Nuclear Medicine (2021)
20. Preparation and Biodistribution Assessment of 68Ga-Dkfz-Psma-617 for Pet Prostate Cancer Imaging, Nuclear Science and Techniques (2016)
21. A Step Toward Simplified Dosimetry of Radiopharmaceutical Therapy Via Spect Frame Duration Reduction, Applied Radiation and Isotopes (2024)
22. Therapeutic Outcomes Of177lu-Psma Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: A Single-Center Study, Asia Oceania Journal of Nuclear Medicine and Biology (2023)
23. Production of the State of the Art Therapeutic Radiopharmaceuticals in Iran, From Beta- to Alpha-Emitting Targeted Radionuclide Therapy: Clinical Advances and Perspectives, Iranian Journal of Nuclear Medicine (2024)